Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis
- PMID: 23355896
- PMCID: PMC3552958
- DOI: 10.1371/journal.pone.0054756
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis
Abstract
This study was conducted to estimate the indirect costs and health-related quality of life (HRQoL) (utilities) of multiple sclerosis (MS) patients in the United States (US), and to determine the impact of worsening mobility on these parameters. In collaboration with the North American Research Committee on Multiple Sclerosis (NARCOMS) registry we conducted a cross-sectional study of participants who completed the biannual update and supplemental spring 2010 survey. Demographic, employment status, income, mobility impairment, and health utility data were collected from a sample of registry participants who met the study criteria and agreed to participate in the supplemental Mobility Study. Mean annual indirect costs per participant in 2011US$ and mean utilities for the population and for cohorts reporting different levels of mobility impairment were estimated. Analyses included 3,484 to 3,611 participants, based on survey completeness. Thirty-seven percent of registrants were not working or attending school and 46.7% of these reported retiring early. Indirect costs per participant per year, not including informal caregiver cost, were estimated at $30,601±31,184. The largest relative increase in indirect costs occurred at earlier mobility impairment stages, regardless of the measure used. Participants' mean utility score (0.73±0.18) was lower than that of a similarly aged sample from the general US population (0.87). As with indirect costs, larger decrements in utility were seen at earlier mobility impairment stages. These results suggest that mobility impairment may contribute to increases in indirect costs and declines in HRQoL in MS patients.
Conflict of interest statement
Figures


Similar articles
-
Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.Neurology. 2006 Jun 13;66(11):1696-702. doi: 10.1212/01.wnl.0000218309.01322.5c. Neurology. 2006. PMID: 16769943
-
Costs and quality of life of multiple sclerosis in Sweden.Eur J Health Econ. 2006 Sep;7 Suppl 2:S75-85. doi: 10.1007/s10198-006-0379-5. Eur J Health Econ. 2006. PMID: 17310342
-
Costs and quality of life of multiple sclerosis in Switzerland.Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9. Eur J Health Econ. 2006. PMID: 17310338
-
Estimate of the cost of multiple sclerosis in Spain by literature review.Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28726515 Review.
-
Improving quality of life in multiple sclerosis: an unmet need.Am J Manag Care. 2011 May;17 Suppl 5 Improving:S139-45. Am J Manag Care. 2011. PMID: 21761952 Review.
Cited by
-
Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12 month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo.BMC Neurol. 2020 Nov 27;20(1):430. doi: 10.1186/s12883-020-01983-y. BMC Neurol. 2020. PMID: 33243182 Free PMC article.
-
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591. Epub 2015 Jan 12. Mult Scler. 2015. PMID: 25583832 Free PMC article. Clinical Trial.
-
An Exploratory Study of Community Mobility in Adults With Multiple Sclerosis Across Different Ambulation Levels.Int J MS Care. 2023 Jul-Aug;25(4):145-151. doi: 10.7224/1537-2073.2022-042. Epub 2023 Feb 27. Int J MS Care. 2023. PMID: 37469334 Free PMC article.
-
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study.Pharmacoeconomics. 2016 Dec;34(12):1255-1265. doi: 10.1007/s40273-016-0435-7. Pharmacoeconomics. 2016. PMID: 27461538
-
Social participation in patients with multiple sclerosis: correlations between disability and economic burden.BMC Neurol. 2014 May 27;14:115. doi: 10.1186/1471-2377-14-115. BMC Neurol. 2014. PMID: 24884720 Free PMC article.
References
-
- Frohman EM (2003) Multiple sclerosis. Med Clin North Am 87: 867–897. - PubMed
-
- Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, et al. (2005) Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 11: 232–239. - PubMed
-
- Nortvedt MW, Riise T, Myhr KM, Nyland HI (1999) Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 53: 1098–1103. - PubMed
-
- Naci H, Fleurence R, Birt J, Duhig A (2010) Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 28: 363–379. - PubMed
-
- Kobelt G, Berg J, Atherly D, Hadjimichael O (2006) Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 66: 1696–1702. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous